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Background: This study compared outcomes of different types of DES used for LMCAD in patients with acute MI.
Methods: A total of 233 patients enrolled in the Korea Acute Myocardial Infarction Registry between Nov. 2005 and Jan. 2008 who underwent 
percutaneous coronary intervention (PCI) with DES for unprotected LMCAD were divided into 3 groups: sirolimus-eluting stents (SES), N=92; 
paclitaxel-eluting stents (PES), N=98; and zotarolimus-eluting stents (ZES), N=43. Clinical outcomes at 30 days, 6 and 12 months were compared.
Results: Baseline clinical and angiographic characteristics were similar among the 3 groups. ST-elevation MI accounted for 50.0%, 51.5%, 
and 46.5% in SES, PES, and ZES groups, respectively (p=0.884). The rate of PCI for isolated LMCAD was 19.6%, 11.2%, and 23.3%, (p=0.137). 
There were no differences in the rates of left ventricular ejection fraction (48.7±14.5% vs. 48.3±13.4% vs. 48.2±15.2%, p=0.971), pre-PCI TIMI 3 
(39.1% vs. 43.9% vs. 39.5%, p=0.778), post-PCI TIMI 3 (92.4% vs. 94.9% vs. 83.7%, p=0.080), stent size, length and number, and peri-procedural 
complications including cardiogenic shock, ventricular arrhythmia, cardiopulmonary resuscitation, intra-aortic balloon counter-pulsation, and 
mechanical ventilation. In-hospital mortality was 12.0%, 10.2%, and 16.3% (p=0.593), respectively. The use of medications including cilostazol 
and statin were similar among the groups during admission and after discharge. One-month clinical outcome was similar with the death/MI rate 
of 12.0%, 13.3%, and 16.3%, respectively (p=0.789). At 6 months, there were no differences in the rates of death/MI (12.0% vs. 14.3% vs. 16.3%, 
p=0.678) and target-lesion revascularization (TLR) (4.3% vs. 3.1% vs. 2.3%, p=0.806). At 12 months, likewise, no statistical difference was noted 
among the groups in the rates of death/MI (13.0% vs. 17.3% vs. 18.6%, p=0.652), TLR (5.4% vs. 3.1% vs. 7.0%, p=0.549), and composite death/
MI/TLR (18.5% vs. 20.4% vs. 25.6%, p=0.635).
Conclusions: The 12-month outcomes with the 3 types of DES were similar in patients with acute MI who underwent PCI for unprotected LMCAD.
